阿斯利康肿瘤业务增长远超Farxiga下滑 (NYSE:AZN)
· seekingalpha.com
阿斯利康以18.46倍远期市盈率估值，具备买入价值；专科药物推动双位数增长，第三季度营收增长7%。更多AZN股票分析请点击。
My research is based on key market themes and works to identify setups that provide asymmetrical risk/reward profiles within these niches. My portfolio is curre...